Rolith and AGC Announce Partnership to Bring Anti-reflective Glass to Market
News Apr 25, 2013
Rolith, Inc. has announced partnership with Asahi Glass Company (AGC), one of the world's largest glass manufacturers.
The joint development agreement reflects a continued partnership between the two companies in commercializing an advanced manufacturing technology in application to the architectural glass market.
Architectural glass commonly used in construction reflects approximately four percent to eight percent of light, which is caused by sharp transition between materials with very different refractive indexes - glass and air.
The resulting glare is undesirable because it interferes with the human eyesight and obstructs visibility.
The advanced anti-reflective glass being developed by Rolith and AGC is based on the "moth eye" approach found in nature - an array of nanostructures mimicking an insect's eye.
Rolith brings to the project its proprietary manufacturing method - Rolling Mask lithography, which enables one to create nanostructures on large area glass panels in a cost effective manner.
The nanostructured anti-reflective glass reduces reflections in an exceptionally wide wavelength spectrum and a wider range of viewing angles over traditional PVD thin films coated glass.
Furthermore, it is also anticipated to have improved environmental stability over competitive products such as polymeric nanostructured films and hybrid organic-inorganic coatings on glass.
"Through this strategic partnership we are able to deliver a truly innovative, high-performance anti-reflective glass," said Dr. Boris Kobrin, founder and CEO, Rolith.
Dr. Kobrin continued, "AGC's commitment demonstrates the significant progress of Rolith's technology to date and together we are now positioned to accelerate development of novel advanced glass products based on our fabrication method."
"AGC has chosen Rolith for their cutting-edge technology and talented team. The strategic partnership demonstrates our confidence in Rolith's capability to move forward with commercialization efforts. We look forward to continue bringing to market exceptional and innovative glass solutions," said Usui Hiroshi, deputy general manager, AGC.
Nanoparticles show great promise as diagnostic tools and drug delivery agents. But until now, most nanoparticles had to be injected into the bloodstream because they weren’t absorbed well orally. Now, researchers have modified nanoparticles to improve their uptake in the gastrointestinal tract.